Definitive Healthcare (NASDAQ:DH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Definitive Healthcare (NASDAQ:DH) from a buy rating to a strong-buy rating in a research report report published on Saturday morning.

A number of other research analysts also recently commented on DH. Morgan Stanley reiterated an “underperform” rating and set a $3.50 price objective on shares of Definitive Healthcare in a research note on Thursday. Barclays cut their target price on shares of Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating on the stock in a research note on Monday, December 8th. Canaccord Genuity Group decreased their price target on Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Monday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definitive Healthcare in a report on Wednesday, October 8th. Finally, William Blair raised Definitive Healthcare to a “strong-buy” rating in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $3.94.

Definitive Healthcare Trading Down 0.4%

NASDAQ:DH opened at $2.53 on Friday. The stock has a market cap of $357.64 million, a price-to-earnings ratio of -1.51 and a beta of 1.60. Definitive Healthcare has a one year low of $2.15 and a one year high of $5.68. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.60 and a current ratio of 1.60. The business’s 50-day simple moving average is $2.70 and its 200 day simple moving average is $3.47.

Definitive Healthcare (NASDAQ:DH) last announced its earnings results on Thursday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. Definitive Healthcare had a positive return on equity of 3.30% and a negative net margin of 77.88%.The company had revenue of $60.05 million for the quarter, compared to analyst estimates of $59.51 million. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS and its Q4 2025 guidance at 0.050-0.060 EPS. As a group, sell-side analysts predict that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DH. Cubist Systematic Strategies LLC raised its stake in Definitive Healthcare by 2,456.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 144,284 shares of the company’s stock valued at $417,000 after acquiring an additional 138,640 shares in the last quarter. Bank of Montreal Can bought a new position in shares of Definitive Healthcare in the second quarter worth $71,000. Nuveen LLC bought a new position in shares of Definitive Healthcare in the first quarter worth $300,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Definitive Healthcare by 44.3% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 361,046 shares of the company’s stock valued at $1,408,000 after purchasing an additional 110,894 shares during the period. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in shares of Definitive Healthcare during the second quarter valued at about $77,000. 98.67% of the stock is currently owned by institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.